CytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress

Company Overview - CytoSorbents Corporation (NASDAQ: CTSO) specializes in blood purification technologies for treating life-threatening conditions in intensive care and cardiac surgery [1][7] - The company's lead product, CytoSorb®, is an extracorporeal cytokine adsorber that mitigates "cytokine storm" in critical illnesses, significantly reducing inflammation and organ failure risks [7] - As of March 31, 2024, over 237,000 CytoSorb devices have been utilized globally, with the product approved in the European Union and distributed in 75 countries [7] Recent Developments - CytoSorbents will present at the 1st Annual American Association of Physicians of Indian Origin (AAPI) World Health Congress from July 18-22, 2024, in New York, engaging with over 3,000 healthcare professionals [1][2] - Dr. Phillip Chan, CEO of CytoSorbents, will participate in a panel discussion on the role of artificial intelligence in healthcare, highlighting the company's historical involvement with DARPA in developing smart diagnostic systems for sepsis [1][6] Product Innovations - The DrugSorb™-ATR system, an investigational device for antithrombotic removal, has received two FDA Breakthrough Device Designations for use in urgent cardiothoracic procedures [3][11] - CytoSorbents' technologies are supported by approximately $50 million in funding from various U.S. government agencies, indicating strong institutional backing for its research and development efforts [8] Market Position - The AAPI represents over 80,000 practicing physicians in the U.S., with its members accounting for about 10% of all physicians and serving approximately 30% of the U.S. patient population, providing a significant platform for CytoSorbents to increase awareness of its technologies [2]